// App-Quantinova.ai

: Neoadjuvant pembrolizumab for cisplatin-ineligible muscle-invasive bladder cancer prior to radical cystectomy.

Researchers

Presenter

  • Kyle M Rose

Principal Investigators

  • Marco Bandini

  • Heather L Huelster

  • Giuseppe Basile

  • Shreyas U Naidu

  • Philippe E. Spiess

  • Andrea Necchi

  • Roger Li

Medical Centers

  • Department of Medical Oncology, San Raffaele Scientific Institute, Milan, Italy

  • Vita-Salute San Raffaele University,

  • H. Lee Moffitt Cancer Center & Research Institute, Riverview, FL

  • IRCCS San Raffaele Milano, Milan, Italy

Locations

  • Italy

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Bladder Cancer

Biomarkers

  • N/A

Drug/Treatment

  • Pembrolizumab

  • Cisplatin

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved